drugset / Trial / NCT03606590

Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)

NCT03606590 ↗

Phase 2 Completed 25 enrolled NovoCure Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The study is a prospective, phase II trial single arm, historical control aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L(P) System, in combination with sorafenib in patient with advanced HCC. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

Timeline

Start
2019-02-15
Primary completion
2021-01-14
Completion
2021-01-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule 400 mg Oral